Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 262 posts found.

shutterstock_159488225

Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

January 31, 2020
Medical Communications, Research and Development Bayer, orion, pharma

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen …

News

NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns

January 20, 2020
Sales and Marketing Bayer, Cancer, NICE, Vitravki

UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …

News
1201709115_133b3927a3_b

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

January 10, 2020
Medical Communications Bayer, Exscientia, oncology

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …

News
shutterstock

Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3

November 19, 2019
Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat

MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …

News

Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy

September 24, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …

News

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …

News
bayercross3

Bayer buys BlueRock Therapeutics for $600 million

August 9, 2019
Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma

Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …

News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

News

Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

July 30, 2019
Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …

News
Bayer image

Bayer’s Gadavist becomes first FDA-approved drug for MRI in coronary artery disease patients

July 16, 2019
Manufacturing and Production, Sales and Marketing Bayer, FDA, Gadavist, coronary artery disease, pharma

The FDA has awarded approval to Bayer’s Gadavist (gadobutrol) injection, the company confirmed.

News
ipos0_l

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

May 14, 2019
Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …

News

Bayer VP elected to two of the firm’s executive committees

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment

Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …

Appointment
shirelabsus

Takeda ordered to pay Bayer $155.19 million over patent infringement

February 6, 2019
Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …

News

Bayer to cut 12,000 jobs by 2025

December 6, 2018
Business Services, Manufacturing and Production, Sales and Marketing Bayer, Germany, Jobs, manfucaturing, monsanto, production

German pharma giant Bayer is set to cut 12,000 jobs by 2025 as part of a plan to focus on …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025